Clinical Trial Market Research Reports & Industry Analysis

“Anti-Lymphotoxin - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Anti-Lymphotoxin development. The report provides detailed coverage of the pipeline landscape for this mechanism of a ...

“Alpha-1 Antagonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Alpha-1 Antagonist development. The report provides detailed coverage of the pipeline landscape for this mechanism ...

“Alpha v Beta 3 Integrin Antagonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Alpha v Beta 3 Integrin Antagonist development. The report provides detailed coverage of the pipeli ...

“Alpha v Beta 3/5/6 Integrin Antagonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Alpha v Beta 3/5/6 Integrin Antagonist development. The report provides detailed coverage of th ...

“Akt1 Inhibitor - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Akt1 Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of actio ...

In our latest quarterly review of corporate sustainability impacts, risks and opportunities, we find that biotechnology and pharmaceutical companies have made substantial ESG commitments. This edition also analyses the effects of government tariffs and trade policy uncertainty on sustainable API sou ...

DelveInsight’s, “Janus Kinase (JAK) Inhibitor- Pipeline Insight, 2025” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Janus Kinase (JAK) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It als ...

DelveInsight’s, “Huntington’s Disease - Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Huntington’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the t ...

DelveInsight’s, “Hypertriglyceridemia - Pipeline Insight, 2025” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Hypertriglyceridemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the th ...

DelveInsight’s, “Sarcopenia - Pipeline Insight, 2025” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Sarcopenia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessmen ...

DelveInsight’s, “Diabetic Nephropathy- Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Diabetic Nephropathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the the ...

DelveInsight’s, “B-cell Lymphoma- Pipeline Insight, 2025” report provides comprehensive insights about 295+ companies and 300+ pipeline drugs in B-cell Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutic ...

DelveInsight’s, “Potassium channel antagonists - Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Potassium channel antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It ...

DelveInsight’s, “Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors - Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors pipeline landscape. It covers the pipeline drug profiles, includ ...

“Transient Receptor Potential Cation Channel, Subfamily M, Member 8 (TRPM8) Antagonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Transient Receptor Potential Cation Channel, Sub ...

“Sigma Receptor Agonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Sigma Receptor Agonist development. The report provides detailed coverage of the pipeline landscape for this me ...

“Kv1.3 Potassium Channel Blockers - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Kv1.3 Potassium Channel Blockers development. The report provides detailed coverage of the pipeline l ...

“Apolipoprotein B (ApoB) Inhibitor - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Apolipoprotein B (ApoB) Inhibitor development. The report provides detailed coverage of the pipeline ...

“Angiotensin Receptor Agonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Angiotensin Receptor Agonist development. The report provides detailed coverage of the pipeline landscape ...

“AMPA Receptor Antagonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across AMPA Receptor Antagonist development. The report provides detailed coverage of the pipeline landscape for thi ...

“Aldose Reductase Inhibitor - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Aldose Reductase Inhibitor development. The report provides detailed coverage of the pipeline landscape for ...

“Aldosterone Antagonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Aldosterone Antagonist development. The report provides detailed coverage of the pipeline landscape for this me ...

“Adenosine A3 Receptor Agonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Adenosine A3 Receptor Agonist development. The report provides detailed coverage of the pipeline landsca ...

Key Highlights According to DelveInsight’s patient-based forecasting model, the oligometastatic disease market size in the 7MM was around USD 1,900 million in 2023, which is expected to significantly increase over the forecast period (2024-2034), owing to an increase in the cases and the launch of n ...

DelveInsight’s, “Microbiome Disease- Pipeline Insight, 2025” report provides comprehensive insights about 140+ companies and 180+ pipeline drugs in Microbiome Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the thera ...